ropinirole IR / Generic mfg. - LARVOL DELTA

Modulating microneedles' array design and application force for personalizing skin permeation using design of experiments. (PubMed, Int J Pharm) - "For this purpose, Ropinirole Hydrochloride (RopHCl) was utilized as model drug due to its hydrophilic nature...Regarding base width, although it does not directly influence drug permeation, it affects the mechanical rigidity. It can be thus concluded that drug permeation through skin can be effectively personalized by tuning the microneedle array properties, while keeping a constant microneedle composition."

Journal

Tramadol for Refractory Restless Legs Syndrome Following Methadone Intolerance: A Case Report. (PubMed, Cureus) - "We present a 52-year-old woman with refractory RLS who failed multiple pharmacologic therapies, including ropinirole, carbidopa/levodopa, gabapentin, and pregabalin. Transition to tramadol 50 mg nightly resulted in sustained symptom control without recurrence of these adverse effects, allowing discontinuation of gabapentin and improved daytime functioning. This case highlights the importance of individualized opioid selection in refractory RLS and suggests that tramadol may be an effective alternative for carefully selected patients with methadone intolerance."

Journal • CNS Disorders • Insomnia • Migraine • Mood Disorders • Movement Disorders • Pain • Psychiatry • Restless Legs Syndrome • Sleep Disorder

Ropinirole adjunct to methylphenidate versus placebo adjunct to methylphenidate for attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled trial. (PubMed, Eur Child Adolesc Psychiatry) - "In conclusion, methylphenidate + ropinirole was safe and beneficial compared to methylphenidate + placebo for reducing inattentive, hyperactive-impulsive, and total symptoms in children with ADHD. Further studies are required."

Clinical • Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Immunology • Inflammation • Psychiatry

From neural development to regenerative medicine: A research journey in stem cell biology, spinal cord repair, and iPSC-based drug discovery. (PubMed, Regen Ther) - "In parallel, we developed patient-derived iPSC platforms for neurological disease modeling and drug discovery, particularly for amyotrophic lateral sclerosis, where iPSC-based screening identified Ropinirole as a therapeutic candidate and enabled reverse translational research linking cellular phenotypes with clinical responses. Looking ahead, I argue that the future of regenerative therapy will depend on the continued integration of developmental biology, stem cell science, disease modeling, rehabilitation, and clinical translation to address unmet medical needs in disorders of the central nervous system."

First-in-human • Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Orthopedics • Transplantation • MBP

Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy-Advances through 2026. (PubMed, Regen Ther) - "The FDA's accelerated approval of tofersen (Qalsody) in April 2023 marked the first treatment targeting a genetic cause of ALS. iPSC-derived drug candidates, including ropinirole and bosutinib, have completed early-phase clinical trials led by Japanese institutions...The identification of STMN2 as a downstream target of TDP-43 dysfunction has opened a potential TDP-43-downstream nucleic acid therapeutic avenue for sporadic ALS, which constitutes approximately 90% of all cases, with company-reported interim data suggesting target engagement in the ongoing Phase 1/2 ANQUR trial (QRL-201). This review synthesizes the latest evidence across all three therapeutic domains, with attention to the hierarchy of evidence, regulatory milestones, and the pioneering contributions of Japanese research groups."

First-in-human • Journal • Review • Amyotrophic Lateral Sclerosis • CNS Disorders • Gene Therapies • Inflammation • Transplantation • STMN2 • TARDBP

The emerging role of NAT10-mediated N4-acetylcytidine modification of RNA in bone diseases: Current frontiers and future challenges. (PubMed, Life Sci) - "NAT10-mediated ac4C modification represents an emerging regulatory mechanism in skeletal biology. Accumulating evidence supports its involvement in osteoporosis, inflammatory bone loss, osteoarthritis, and osteosarcoma through effects on RNA stability, translation efficiency, and downstream signaling. Substantial gaps nonetheless remain. In particular, it is still unclear how ac4C on specific transcripts controls bone- and cartilage-cell function, and to what extent these modifications are dynamically regulated across disease states."

Journal • Review • Dental Disorders • Immunology • Oncology • Orthopedics • Osteoarthritis • Osteoporosis • Osteosarcoma • Pain • Periodontitis • Rheumatoid Arthritis • Rheumatology • Sarcoma • Solid Tumor • NFATC1 • RUNX2

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study. (PubMed, Clin Neuropharmacol) - "Pre-existing peak-dose dyskinesia and lower body weight independently influence the need for ropinirole patch dose modification after switching. Individualized dose titration is recommended, particularly in light-weight patients or those with dyskinesia, and prospective studies are warranted to refine dose conversion strategies."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Baseline dopaminergic treatment profiles of patients with advanced Parkinson’s disease prior to Levodopa-Entacapone-Carbidopa intestinal gel infusion (EAN 2026) - "Most patients also had treatment with dopamine agonists (82%; pramipexole n = 10, 2.35 ± 0.87 mg; ropinirole n = 11, 12.36 ± 5.5 mg; rotigotine patch n = 21, 8.48 ± 1.89 mg) as well as selective monoamine oxidase B inhibitors (MAO-Bi, 60%, n = 30), apomorphine pen (14%, n = 7), Amantadine (28%, n = 14) and Entacapone (70%, n = 35). The usage of dopaminergic treatments in patients with APD prior to LECIG treatment was more complex than those described in the literature. Such analyses help general neurologists identify the limits of conventional dopaminergic therapy and prompt timely referral to tertiary centers."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Quality by design-based development of transferrin-functionalized nanostructured lipid carriers for targeted Co-delivery of ropinirole and mangiferin for improved drug-delivery to the brain. (PubMed, Int J Biol Macromol) - "Furthermore, results obtained from gamma scintigraphy study revealed that Tf-RP-MF-NLC had enhanced brain targeting and increased drug accumulation as compared to RP-MF-NLC following intraperitoneal (i.p.) administration. Overall, these findings highlights Tf-RP-MF-NLC as a promising brain targeted nanocarrier system with improved drug delivery, suggesting its potential as an effective therapeutic strategy for improved drug delivery to the brain."

Journal • Cardiovascular • Hematological Disorders • Ischemic stroke

Isocratic zwitterionic HILIC-ESI-MS method for assay of ropinirole and quantitation of degradation impurities in extended-release tablets. (PubMed, Talanta) - "The method was successfully applied to the analysis of commercially available ropinirole extended-release tablets. To the best of our knowledge, this is the first reported HILIC-ESI-MS method for the assay of ropinirole and the quantitation of three degradation impurities in pharmaceutical tablets."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Recurrent bradycardia and hypotension after Oral Lacosamide during hospital boarding in the emergency department: A case report. (PubMed, Am J Emerg Med) - "We report a case of a 79-year-old woman with a history of hypertension (treated with losartan and metoprolol), restless legs syndrome (treated with ropinirole), peripheral neuropathy, and seizure disorder who presented to the emergency department with several days of intermittent confusion and generalized weakness following a recent admission for seizure-like activity, during which lacosamide had been initiated...She responded to atropine 1 mg IV and 50μg of epinephrine IV, with improvement of her vital signs and mental status. Six hours later, she received a second scheduled dose of lacosamide 150 mg along with her home medications, including metoprolol tartrate 50 mg, and again two hours later became minimally responsive with a heart rate of 49 beats per minute, blood pressure 64/32 mmHg, and a new first-degree atrioventricular block; she again responded to atropine...Emergency physicians should maintain a high index of suspicion for..."

Journal • Cardiovascular • CNS Disorders • Epilepsy • Hypertension • Hypotension • Movement Disorders • Pain • Restless Legs Syndrome • Sleep Disorder

The prevalence of impulse control issues with dopamine agonists: A patient-led survey (WPC 2026) - "Methods We conducted a survey of people in the UK who are currently taking, or had previously taken, either ropinirole, rotigotine or rotigotine to treat the symptoms of Parkinson’s disease. Results (1) 24% of respondents reported issues with significant impact, 39% reported issues with moderate impact and 37% reported no issues (2) Changes of behaviour related to shopping (20% of respondents), gambling (7%), sex (37%), binge eating (20%), online gaming (20%) and other obsessive behaviour (20%) (3) 52% of respondents either did not report or played down the severity of impulse control issues when speaking with their medical team (4) Men are more likely than women to experience issues with a significant impact, and men are more likely to experience sex related issues (5) The incidence of issues across the three drugs is similar, but the severity varies with pramipexole more likely to lead to issues with a significant impact and rotigotine the least likely to lead to..."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Human iPSC‑based translational and reverse translational research for neurodegenerative diseases: emphasis on ALS and key advances. (PubMed, Jpn J Radiol) - "Key clinical trials launched from iPSC screens-ropinirole, retigabine and bosutinib-are reviewed alongside emerging rTR efforts that use patient‑derived iPSCs to identify biomarkers and therapeutic mechanisms. We also survey iPSC models for AD, PD and HD, highlighting applications of three‑dimensional (3D) brain organoids and gene‑editing technologies. Finally, we discuss future directions for precision medicine, multimodal integration and technological challenges, with particular attention to how imaging biomarkers may complement iPSC-based TR/rTR frameworks in neurodegenerative diseases."

Journal • Review • Alzheimer's Disease • Amyotrophic Lateral Sclerosis • CNS Disorders • Huntington's Disease • Movement Disorders • Parkinson's Disease

Ex Vivo Characterization and In Vivo Nasal Delivery of Ropinirole-Loaded PEO-b-PCL/Tween 80/β-Cyclodextrin Systems in C57BL/6J Mice. (PubMed, Molecules) - "Pharmacokinetic analysis showed that F4 significantly enhanced both systemic and brain exposure of RH, achieving higher serum AUC and Cmax values, despite a 3-fold lower administered dose compared to the oral dose. It showed high systemic (Frel(Serum) = 1815%) and brain (Frel(Brain) = 363%) relative bioavailability compared with oral administration, underscoring its potential as an intranasal delivery system for efficient CNS targeting."

Journal • Preclinical

Delayed-onset Parkinsonism Following BCMA-directed CAR-T Therapy (AAN 2026) - "He received high-dose dexamethasone with a prednisone taper. He showed poor response to sequential monotherapies, including carbidopa/levodopa, carbidopa/levodopa plus entacapone, ropinirole and rotigotine. Combination therapy with rotigotine, amantadine, and levodopa induced hallucinations. Midodrine improved orthostasis, but overall pharmacological response was minimal...Conclusions This case underscores MNT as a significant delayed complication of BCMA-directed CAR-T therapy, aligning with European Society for Blood and Marrow Transplantation (EBMT) guidelines. It emphasizes the need for extended neurological surveillance, recognition of limited dopaminergic therapy efficacy, early immunomodulatory interventions despite inconsistent results and involvement in registries to better elucidate prevalence, underlying mechanisms, and optimal management strategies."

CAR T-Cell Therapy • IO biomarker • CNS Disorders • Depression • Gastrointestinal Disorder • Hematological Malignancies • Hypotension • Infectious Disease • Inflammation • Movement Disorders • Multiple Myeloma • Parkinson's Disease • Septic Shock

Pharmacokinetic evaluation of intranasal ropinirole delivery using hybrid polymer/surfactant/βCD systems in C57BL/6J mice. (PubMed, Int J Pharm) - "The pre-eminence of the nasal formulations is witnessed by higher serum AUC and Cmax values after intranasal administration of formulations compared to the per os administration of RH solution. Notably, the intranasal administration of the RH powder resulted in the highest systemic bioavailability (Frel(Serum) = 1497 %) and brain exposure (Frel(Brain) = 541 %), suggesting a promising role for nasal delivery in targeting the CNS."

Journal • PK/PD data • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Clinical aspects of impulsive-compulsive behaviors under dopaminergic treatment-A scoping review. (PubMed, Australas Psychiatry) - "Younger age, male sex and dopamine agonist treatment, especially with pramipexole and ropinirole, were ICB risk factors. Management mainly involved tapering or discontinuing dopamine agonist treatment.ConclusionICBs in PD patients are well characterized, but under-recognition in health care and limited treatment strategies persist. Iatrogenic ICBs in other patient populations remain poorly studied."

Journal • CNS Disorders • Depression • Endocrine Disorders • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Restless Legs Syndrome • Sleep Disorder

Formation Mechanism of N-Despropyl Ropinirole in Ropinirole Hydrochloride Extended-Release Tablets: Nucleophilic Oxidation or Free Radical-Mediated Oxidation? (PubMed, Pharm Res) - "Degradation of ropinirole in the ropinirole hydrochloride extended-release tablets is most likely to proceed via a free radical-mediated oxidative pathway, rather than a nucleophilic oxidative pathway. The forced degradation experiment using H218O is consistent with the proposed free radical-mediated degradation mechanism. The source of the free radicals seems to originate from the two excipients, CMC-Na and HPMC. The results obtained in the current study would be quite beneficial for further improvement of the drug product in terms of controlling its major degradation pathway."

Journal

Efficacy of Clotiazepam for Respiratory Dyskinesia in a Patient With Parkinsonism: A Case Report. (PubMed, Cureus) - "These symptoms became prominent following the upward titration of a ropinirole patch to 24 mg/day. Although mirtazapine was subsequently added to address comorbid depressive symptoms, it failed to alleviate his respiratory distress...Our findings suggest that the anxiolytic and GABA-mediated muscle-relaxant properties of clotiazepam, combined with its favorable safety profile for the elderly due to its short half-life, may provide a useful and effective new therapeutic option for the management of refractory respiratory dyskinesia. Although the limitations of drawing conclusions from a single case must be acknowledged, these results warrant further large-scale prospective studies to validate the efficacy and safety of clotiazepam in this population."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Pulmonary Disease

Dopamine receptor subtypes modulate the excitability of dorsal root ganglion neurons. (PubMed, Neurosci Lett) - "Activation of D1-like receptors by SKF38393 caused a depolarizing shift in the action potential threshold in small sized DRGs whereas an increase in spike width was observed both in small and large sized DRG neurons, suggesting reduced excitability likely mediated through modulation of sodium channel activity, whereas activation of D2-like receptor by ropinirole reduced the action potential amplitude and modulated the repolarization dynamics in small sized DRGs, indicating potential involvement of Gi-coupled mechanisms affecting sodium and potassium currents. Together, these findings demonstrate subtype-specific modulation of DRG excitability by dopamine and highlight the peripheral dopaminergic system as a critical regulator of nociceptive signalling with potential implications for pain management."

Journal • Pain

Validation of a flow cytometric competitive efflux assay for assessing clinically important drugs as canine P-glycoprotein substrates. (PubMed, Am J Vet Res) - "Mean fluorescence intensity (MFI) ratios 5 but 10 indicate strong P-gp substrates [loperamide (positive control), and moxidectin]. The competitive efflux assay is a useful tool for screening drugs as canine P-gp substrates. These results imply that P-gp-deficient dogs may be at increased risk of adverse effects if treated with apomorphine, capromorelin, enrofloxacin, or moxidectin, depending on the dose administered."

Journal

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

The Challenge of Restless Leg Syndrome and Obstructive Sleep Apnea (co-rosa) in Hospitalized Patients on Ropinirole (ATS 2026) - No abstract available

Clinical • Movement Disorders • Obstructive Sleep Apnea • Respiratory Diseases • Restless Legs Syndrome • Sleep Disorder

UnaWireD-ROP: THE EFFECT OF ROPINIROLE ON FUNCTIONAL CONNECTIVITY AND METACOGNITION IN HEALTHY SUBJECTS (clinicaltrialsregister.eu) - P2/3 | N=20 | Not yet recruiting | Sponsor: Universita' Degli Studi Di Modena E Reggio Emilia

New P2/3 trial

Restless legs syndrome treatment - gabapentinoids or dopamine agonists? (PubMed, Neurol Neurochir Pol) - "The first-line treatment options with a "strong recommendation" are now gabapentinoids (gabapentin, gabapentin enacarbil, pregabalin) along with intravenous ferric carboxymaltose...In older patients with co-morbidities in whom gabapentinoids are not well tolerated it results in relatively high rates of withdrawal. In this point of view paper, we present our personal views (supported by clinical data) on the need for both groups of medications in clinical practice because none of them is free of potential side effects and may still be useful."

Journal • Movement Disorders • Restless Legs Syndrome • Sleep Disorder